FindTrial
Sign In

Personalized approach to predict and manage the cardiac side effects of anthracyclines in breast cancer patients

Pharmacogenomics and Population Pharmacokinetics Approaches for Prediction and Management of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/108571
Enrollment
300
Registered
2026-04-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Anusandhan National Research Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Female patients aged greater than 18 years with a histologically confirmed diagnosis of breast cancer. Patients willing to provide peripheral blood samples for: Pharmacogenomic analysis and Population pharmacokinetic (PopPK) evaluation. Patients planned to receive anthracycline-based chemotherapy either as neoadjuvant, adjuvant, or metastatic therapy.

Exclusion criteria

Exclusion criteria: Patients with pre existing significant cardiac disease

Design outcomes

Primary

MeasureTime frame
Genotype-specific risk of CTRCD-defined cardiotoxicity following anthracycline therapy Timepoint: Genotype-specific risk of CTRCD-defined cardiotoxicity will be assessed at Baseline,Post Chemotherapy Cycle 2, Post Chemotherapy Cycle 4, 6 and 12 months following anthracycline therapy.—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactMurali Munisamy

All India Institute of Medical Sciences Bhopal

murali.tmc@aiimsbhopal.edu.in9600883284

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026